Live Breaking News & Updates on Localized Gemcitabine

Stay updated with breaking news from Localized gemcitabine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial. ....

United States , Siamak Daneshmand , American Urological Association Annual Meeting , Clinical Research , Bacillus Calmette Gu , Urological Association Annual , Keck Medicine , Patients With Bacillus Calmette Guérin Unresponsive , High Risk Non Muscle Invasive Bladder Cancer , Tar 200 , Phase 2b Sunrise 1 Trial , Localized Gemcitabine , Novel Intravesical Delivery System ,